About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

NCT00147719·48 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Daiichi Sankyo

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age 18-75 years, inclusive
Diagnosed with type 2 diabetes
Hemoglobin (HbA1c) between 7.5% to 9.5%
Prescribed an ADA accepted diet
Receiving stable dose of metformin alone or in combination with other oral anti-diabetic medications for 90 days before Visit 1

You may not be if

History of type 1 diabetes or ketoacidosis
History of chronic (more than 2 months) insulin therapy or the initiation of insulin for chronic treatment
History of pancreatitis
Uncontrolled hypertension
Recent severe cardiovascular disease
Allergy or toxic response to colesevelam or any of its components
Body mass index (BMI) \>45 kg/m2

The record

StatusCompleted

PhasePhase 3

Taking part300

StartedJun 2004

UpdatedJan 18, 2012

Conditions

Type 2 Diabetes

Where48

CRO
Jonesboro, Arkansas, United States
Beverly Hills, California, United States
Carmichael, California, United States

Clareo Health | WelChol® With Metformin in Treating Patients With Type 2 Diabetes